Pune-based Serum Institute of India (SII) has applied for full market authorisation for the COVID-19 vaccine Covishield with the drug regulator. SII CEO Adar Poonawala confirmed that the institute has applied for full market authorisation of the drug, stating supplies of the COVID-19 vaccine have exceeded 125 crore doses.
“Supplies of the COVISHIELD vaccine in India, have exceeded 1.25 billion doses. The government of India now has enough data for full market authorisation, and therefore @SerumInstIndia has applied to the @CDSCO_INDIA_INF (DCGI) and @MoHFW_INDIA for this permission,” Poonawala said in a tweet tagging the Central Drugs Standard Control Organisation (CDSCO) and Ministry of Health and Family Welfare.
SII had partnered with the developer of Covishield, AstraZeneca, for the supply of the vaccine to the government. The vaccine was granted Emergency Use Authorisation (EUA) in January this year.
Covishield has been one of the main Covid-19 vaccines used in India for inoculation. Around 90% population have got Covishield.
Latest India News